Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?
2015 NCCN Annual Conference
Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.
Leora Horn, MD, MSc
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Ingrid A. Mayer, MD
Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Hans Gerdes, MD
Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.
William G. Wierda, MD, PhD
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.
Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and others.